Program
rufinamide
Also written as “Rufinamide”, “SYN111” and “Rufinamide (E2080)”.
Its studies are mostly in Lennox Gastaut Syndrome · Epilepsy · Generalized Anxiety Disorder, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eisai | 50 open or running | phase 3since Jun 7, 2006 | Jun 7, 2006 | none ahead |
| Acorda Therapeutics | 10 open or running | phase 2since Jan 7, 2008 | Jan 7, 2008 | none ahead |
| Daiichi Sankyo | 10 open or running | phase 1since Dec 13, 2024 | Dec 13, 2024 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 7, 2006First study: phase 3 study in EpilepsyNew to EisaiEisai · NCT00334958 · 356 enrolled · United States
- Mar 15, 2007Phase 3 study in EpilepsyEisai · NCT00448539 · 286 enrolled · United States
- Jan 7, 2008Acorda Therapeutics's first study: phase 2 study in Generalized Anxiety DisorderNew to Acorda TherapeuticsAcorda Therapeutics · NCT00595231 · 239 enrolled · United States
- Jun 14, 20102 phase 3 studies in Lennox Gastaut SyndromeEisai · NCT01151540, NCT01146951
- Jul 27, 2011Phase 3 study in Lennox Gastaut SyndromeEisai · NCT01405053 · 37 enrolled · United States, Canada, France and more
- Dec 13, 2024Daiichi Sankyo's first study: phase 1 study in Healthy SubjectsNew to Daiichi SankyoDaiichi Sankyo · NCT06740825 · 32 enrolled · United States
TargetBeta
“Sodium channel alpha subunit blocker”ChEMBL 37, by rule
Other programs on the same 10 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Lidocainerule | Keenova Therapeutics | phase 4 | 63 |
| Lamotriginerule | GlaxoSmithKline | phase 4 | 61 |
| Carbamazepinerule | grin-therapeutics-inc | phase 4 | 21 |
| Dronedaronerule | Sanofi | phase 4 | 18 |
| chloroprocainerule | sintetica-sa | phase 4 | 8 |
| Riluzolerule | Sanofi | phase 4 | 6 |
| Prilocainerule | Haisco Pharmaceutical Group | phase 4 | 2 |
| Carticainerule | Laboratoires Thea | phase 4 | 1 |
| Ropivacainerule | painreform-ltd | phase 3 | 17 |
| Phenytoinrule | Viatris | phase 3 | 10 |
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06740825Healthy Subjects · United States | 1 | Completed | Daiichi Sankyo | Dec 9, 2024 | 32 |
| NCT01405053Lennox Gastaut Syndrome · United States, Canada, France and more | 3 | Completed | Eisai | Nov 2, 2015 | 37 |
| NCT01151540Lennox Gastaut Syndrome · Japan | 3 | Completed | Eisai | Aug 2013 | 54 |
| NCT01146951Lennox Gastaut Syndrome · Japan | 3 | Completed | Eisai | Aug 2011 | 66 |
| NCT00595231Generalized Anxiety Disorder · United States | 2 | Completed | Acorda Therapeutics | Oct 2008 | 239 |
| NCT00448539Epilepsy · United States | 3 | Terminated | Eisai | May 14, 2010 | 286 |
| NCT00334958Epilepsy · United States | 3 | Completed | Eisai | May 20, 2009 | 356 |
How it is read
Names in the registry
- “Rufinamide”, 5 entries
- “SYN111”, 1 entry
- “Rufinamide (E2080)”, 1 entry
Conditions, from the studies’ own filings
- Lennox Gastaut Syndrome, 3 studies
- Epilepsy, 2 studies
- Generalized Anxiety Disorder, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.